Depression: EU approves expanded use of esketamine for rapid reduction of symptoms
Approval of esketamine for treatment-resistant depression - The Lancet Psychiatry
Full article: Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the
Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-acc
Frontiers | Efficacy and Safety of Intranasal Esketamine in Patients With Treatment-Resistant Depression and Comorbid Chronic Post-traumatic Stress Disorder: Open-Label Single-Arm Pilot Study
J&J builds case for Spravato in tough-to-treat depression
EMA Tracker: HCPs Anticipating 2020 Approval | Knowledge | CREATION.co
EMA Tracker: HCPs Anticipating 2020 Approval | Knowledge | CREATION.co
PDF) Case report: Effectiveness of brexpiprazole and esketamine/ketamine combination: A novel therapeutic strategy in five cases of treatment-resistant depression
SPRAVATO®▽ (Esketamine) Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder | Business Wire
Esketamine for treatment resistant depression: a trick of smoke and mirrors? | Epidemiology and Psychiatric Sciences | Cambridge Core
Spravato, INN-esketamine
esketamine
EMA Tracker: HCPs Anticipating 2020 Approval | Knowledge | CREATION.co
Characteristics of the three short-term esketamine efficacy trials... | Download Scientific Diagram
Janssen Announces U.S. FDA Approval of SPRAVATO™ (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief
EMA Panel Backs Esketamine Nasal Spray for Resistant Depression
esketamine: List of nationally authorised medicinal products - PSUSA/00001266/201608
SPRAVATO®▽ (Esketamine) Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder | Business Wire
Characteristics of the three short-term esketamine efficacy trials... | Download Scientific Diagram
EU regulators review Janssen's esketamine nasal spray antidepressant | pharmaphorum
JANSSEN RECEIVES POSITIVE CHMP OPINION FOR SPRAVATO® (ESKETAMINE) NASAL SPRAY FOR ADULTS WITH TREATMENT-RESISTANT MAJOR DEPRESS
CHMP selects drugs for EU market approval - European Biotechnology
